Overview

A Study for Participants With Small-Cell Lung Cancer

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Lenograstim
Sargramostim